Drug

Gilead Heightens Inflammatory Disease Focus With Second Genome Microbiome Deal

Gilead Heightens Inflammatory Disease Focus With Second Genome Microbiome Deal

2 hours ago   |   Xconomy

Gilead Sciences has signed an agreement with South San Francisco biotech Second Genome to use its microbiome drug development expertise to advance the compounds it is...
Read more ...

Experimental anti-malarial drug shows promise in first clinical trial

3 hours ago   |   ScienceDaily

Malaria is a leading killer of children worldwide, and new drugs are needed. New research reports encouraging early clinical results with a new compound.
Read more ...

Organovo Future Unclear After Shareholders Reject Tarveda Merger

Organovo Future Unclear After Shareholders Reject Tarveda Merger

6 hours ago   |   Xconomy

A planned merger between struggling 3-D “bioprinter” Organovo and Tarveda Therapeutics, a privately held cancer drug developer looking to join the public markets through a...
Read more ...

Roche Pays $190M to Start RNA Drug Alliance With Arrakis Therapeutics

Roche Pays $190M to Start RNA Drug Alliance With Arrakis Therapeutics

11 hours ago   |   Xconomy

Some diseases have proven difficult to address using conventional tools of drug discovery that target disease-causing proteins. Roche is placing a $190 million bet on Arrakis...
Read more ...

Keros upsizes IPO, raising $96M for blood and musculoskeletal trials

13 hours ago   |   Fierce Biotech   |   2 articles

Keros Therapeutics has braved a turbulent market to pull off an IPO, hitting the top end of its price range and selling 20% more shares than originally planned. The upsized IPO...
Read more ...

Keros Therapeutics Raises $96M in Upsized IPO to Fuel Clinical Tests

Keros Therapeutics Raises $96M in Upsized IPO to Fuel Clinical Tests

15 hours ago   |   Xconomy   |   2 articles

The financial markets may remain volatile but Keros Therapeutics managed to raise more money in its public market debut than it had initially planned. Late Tuesday the...
Read more ...

Sage Restructuring Halves Staff, Turns Focus to Failed Depression Drug

Sage Restructuring Halves Staff, Turns Focus to Failed Depression Drug

21 hours ago   |   Xconomy

Sage Therapeutics is cutting workers who sell its only commercialized drug in a corporate reorganization that it says allows it to focus on clinical-stage compounds, including...
Read more ...

Wellcome targets $8B raise in weeks to fix COVID-19 funding gap

1 day ago   |   Fierce Biotech   |   2 articles

Wellcome is calling on businesses to invest in an $8 billion fund focused on reducing cases of COVID-19 to zero as soon as possible. Almost half the money is earmarked for the...
Read more ...

Dual-Layer Strengthened Collaborative Topic Regression Modeling for Predicting Drug Sensitivity

1 day ago   |   IEEE/ACM

An effective way to facilitate the development of modern oncology precision medicine is the systematical analysis of the known drug sensitivities that have emerged in recent...
Read more ...

Accelerating Therapeutics for COVID-19: Apr 08, 2020

1 day ago   |   San Diego Biotechnology   |   2 articles

Event presented by CertaraTo accelerate COVID-19 therapeutics to patients worldwide, we need a smarter and more modern approach to drug development. The COVID-19 Therapeutics...
Read more ...


Register you to post on BioTech Mag

Free Registration

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Keros Therapeutics Raises $96M in Upsized IPO to Fuel Clinical Tests

Keros Therapeutics Raises $96M in Upsized IPO to Fuel Clinical Tests

The financial markets may remain volatile but Keros Therapeutics managed to raise more money in its public market debut than it had initially planned. Late Tuesday the... Read more ...

Gilead Heightens Inflammatory Disease Focus With Second Genome Microbiome Deal

Gilead Heightens Inflammatory Disease Focus With Second Genome Microbiome Deal

Gilead Sciences has signed an agreement with South San Francisco biotech Second Genome to use its microbiome drug development expertise to advance the compounds it is... Read more ...

Organovo Future Unclear After Shareholders Reject Tarveda Merger

Organovo Future Unclear After Shareholders Reject Tarveda Merger

A planned merger between struggling 3-D “bioprinter” Organovo and Tarveda Therapeutics, a privately held cancer drug developer looking to join the public markets through a... Read more ...

In Battle Against COVID-19 Pandemic, Scientists Turn to PacBio Sequencing

In Battle Against COVID-19 Pandemic, Scientists Turn to PacBio Sequencing

Image by Miroslava Chrienova from Pixabay Our team is proud to announce that PacBio has been working closely with customers to help in the fight against the COVID-19 pandemic... Read more ...

Roche Pays $190M to Start RNA Drug Alliance With Arrakis Therapeutics

Roche Pays $190M to Start RNA Drug Alliance With Arrakis Therapeutics

Some diseases have proven difficult to address using conventional tools of drug discovery that target disease-causing proteins. Roche is placing a $190 million bet on Arrakis... Read more ...

Inovio Begins Experimental COVID-19 Vaccine Tests in Healthy Volunteers

Inovio Begins Experimental COVID-19 Vaccine Tests in Healthy Volunteers

Inovio Pharmaceuticals, one of the biotechs developing a vaccine to prevent COVID-19, has received the FDA's OK to start testing its candidate in healthy volunteers. The... Read more ...

Sage Restructuring Halves Staff, Turns Focus to Failed Depression Drug

Sage Restructuring Halves Staff, Turns Focus to Failed Depression Drug

Sage Therapeutics is cutting workers who sell its only commercialized drug in a corporate reorganization that it says allows it to focus on clinical-stage compounds, including... Read more ...

Creating Consistent Value in Biotech Without Diluting Stakeholders

Creating Consistent Value in Biotech Without Diluting Stakeholders

One of the greatest challenges for pre-commercial biotech companies is consistently generating capital necessary for operating costs and for R&D of new products that provide... Read more ...

Interactive, Online Xcelerating Life Sciences Boston Event Set for May 13

Interactive, Online Xcelerating Life Sciences Boston Event Set for May 13

In the Boston biotech hub, much progress has been made advancing digital health, but significant scientific, technological, financial, and regulatory challenges remain. Join us... Read more ...

Bioinspired reorientation strategies for application in micro/nanorobotic...

Abstract Engineers have recently been inspired by swimming methodologies of microorganisms in creating micro-/nanorobots for biomedical applications. Future medicine may be... Read more ...